Welcome to our dedicated page for Bio-Techne SEC filings (Ticker: TECH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bio-Techne Corporation (NASDAQ: TECH) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Bio-Techne’s life sciences business, which focuses on tools, bioactive reagents, diagnostics, and spatial biology products for research and clinical diagnostic communities.
Investors can review current reports on Form 8-K, where Bio-Techne discloses material events such as quarterly and annual financial results and the declaration of cash dividends. For example, recent 8-K filings reference press releases describing results of operations, financial condition, and dividend announcements. These documents help readers understand revenue trends, segment performance for the Protein Sciences and Diagnostics and Spatial Biology segments, and key corporate actions.
Bio-Techne’s proxy statements on Schedule 14A provide insight into corporate governance, board composition, executive compensation, and shareholder proposals. The company’s definitive proxy statement discusses its mission to improve the quality of life by catalyzing advances in science and medicine, outlines its four growth pillars, and describes how the board oversees strategy, risk, and sustainability initiatives, including greenhouse gas emission reduction commitments.
Annual and quarterly reports on Forms 10-K and 10-Q, when accessed through EDGAR, contain segment disclosures, risk factors, and management’s discussion and analysis relevant to Bio-Techne’s life science tools and diagnostics operations. Filings related to shareholder meetings also detail voting results on director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm.
On Stock Titan, these TECH filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand what changed and why it matters. Real-time updates from EDGAR, combined with structured access to 8-Ks, proxy statements, and other filings, make this page a useful resource for tracking Bio-Techne’s regulatory disclosures and governance information.
A holder of Bio-Techne (TECH) common stock filed a Rule 144 notice to sell 1976 shares through Morgan Stanley Smith Barney on or around 02/17/2026 on NASDAQ, with an aggregate market value of $116791.48.
The shares to be sold are part of the company’s common stock, which had 156453292 shares outstanding listed as a baseline figure. The seller acquired these 1976 shares on 02/14/2025 by exercising previously granted stock options and paid the purchase price in cash.
Bio-Techne Corporation announced a leadership change in its Diagnostics and Spatial Biology Segment, with Dr. Matt McManus transitioning from his role and Steve Crouse, currently Senior Vice President of the Analytical Solutions Division, becoming segment president effective March 1, 2026.
Crouse’s executive employment agreement provides a $505,000 annual base salary and a target annual cash bonus equal to 75% of base pay, plus eligibility for standard employee benefits. He will receive a one-time equity grant of stock options and restricted stock units valued at approximately $170,000 in total at target, and ongoing annual equity awards with grant date values of $300,000 in stock options, $300,000 in time-vested restricted stock units, and $600,000 in performance-based restricted stock units at target. If terminated without cause, after a change in control, or for good reason, he is entitled to one year of base salary, a prorated bonus, and one year of health coverage, subject to a release of claims. The Board approved the termination of McManus’s employment without cause, making him eligible for severance under his agreement. The company highlights that it generated over $1.2 billion in net sales in fiscal 2025 and employs about 3,100 people worldwide.
Bio-Techne director Amy E. Herr reported routine equity activity on 02/03/2026, mainly involving awards held by her significant other. On that date, 38 restricted stock units converted into 38 shares of common stock at $0, all held indirectly through her significant other.
To cover withholding obligations, 16 indirectly held common shares were disposed of at $64.63 per share, leaving 2,176 common shares indirectly held by her significant other and 2,680 shares held directly. The filing also lists multiple stock options and additional restricted stock units with vesting dates from 2026 through 2035, all either directly held or indirectly held through her significant other.
Bio‑Techne reported essentially flat revenue but stronger profits for the quarter ended December 31, 2025. Net sales were $295.9 million versus $297.0 million a year earlier, while net earnings rose to $38.0 million from $34.9 million. Diluted EPS increased to $0.24 from $0.22.
GAAP gross margin slipped to 64.6% from 65.3%, and adjusted gross margin fell to 68.5% from 70.5%, mainly from product mix. Selling, general and administrative expenses declined 6% to $113.7 million as cost management and restructuring took hold.
The Protein Sciences segment grew sales 2% to $215.1 million but saw lower margins, while Diagnostics and Spatial Biology reported a 4% sales decline to $81.2 million but a much stronger 10.4% operating margin, helped by the Exosome Diagnostics divestiture and efficiency initiatives. Operating cash flow was $110.0 million for the six months, and debt under the credit facility fell to $260.0 million.
Bio-Techne Corporation reported that it issued a press release on February 4, 2026 describing its results of operations for the quarter and six months ended December 31, 2025 and its financial condition as of that date. The company also issued a separate press release on the same day announcing a cash dividend, which is attached as another exhibit.
Bio-Techne Corp President – Diag & Spatial Bio, Matthew McManus, reported equity award activity in company stock. On February 1, 2026, 4,621 restricted stock units converted into the same number of common shares at $0 per share. On the same date, 1,665 common shares were withheld at $64.09 per share to cover obligations, leaving 7,691 common shares held directly.
McManus continues to hold multiple equity awards, including performance restricted stock units and stock options that vest over several future dates and run through expiration dates up to August 15, 2035. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Bio‑Techne (TECH) Chief Executive Officer and Director Kim Kelderman reported an insider transaction. On 11/03/2025, he disposed of 2,303 shares of common stock at $62.57 under transaction code F, and now directly holds 48,665 shares.
The filing also lists multiple derivative awards outstanding, including stock options and restricted stock units. Examples include stock options covering 90,441 shares at an exercise price of $53.60 expiring on 08/15/2035, and performance RSUs covering 70,708 shares subject to performance-based vesting.
Bio-Techne (TECH) reported insider transactions by its CFO on 11/03/2025. The executive acquired company stock through RSU vesting and surrendered shares to cover taxes.
Two RSU conversions (code M) added 13,159 shares and 11,545 shares at $0. A tax withholding transaction (code F) disposed of 11,865 shares at $62.57. Following these transactions, the CFO directly owned 142,722 shares.
These actions reflect routine equity award vesting and associated tax settlement rather than an open‑market purchase or sale.
Bio‑Techne (TECH) reported an insider equity event by its President, Protein Sciences. On 11/03/2025, 9,911 shares were acquired at $0 upon settlement of restricted stock units, followed by the disposition of 4,520 shares at $62.57, typically associated with tax withholding. After these transactions, the officer directly owned 20,503 common shares.
The filing also lists outstanding equity awards, including stock options with expirations through 2035 and various time- and performance-based RSUs, indicating future vesting schedules tied to service and performance conditions.
Bio‑Techne (TECH) reported Q1 FY2026 results. Net sales were $286.6 million versus $289.5 million a year ago as Protein Sciences softened while Diagnostics & Spatial Biology improved organically. Gross margin rose to 65.6% from 63.2%, and operating income increased to $47.7 million from $40.0 million. Net earnings were $38.2 million with diluted EPS of $0.24, up from $0.21.
Cash flow from operations was $27.6 million. Cash and equivalents were $145.0 million, and long‑term debt decreased to $300.0 million from $346.0 million, reflecting $46.0 million in repayments. Segment detail: Protein Sciences sales were $202.2 million (down 1%), operating margin 38.4%; Diagnostics & Spatial Biology sales were $79.5 million (down 4% reported; organic growth 3%), operating margin 11.2% versus 5.1%. The quarter included a $6.8 million recovery related to the Exosome Diagnostics divestiture and receipt of MDxHealth stock valued at $8.7 million. EMEA (ex‑UK) grew, while the United States declined year over year.